927801-23-8

Basic information

• Product Name: 6-BROMO-4-IODOQUINOLINE
• Synonyms: 6-BROMO-4-IODOQUINOLINE
• CAS NO: 927801-23-8
• Molecular Formula: C₉H₅BrIN
• Molecular Weight: 333.95
• EINECS: 200-258-5
• Mol File: 927801-23-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 375.5 °C at 760 mmHg
• Flash Point: 180.9 °C
• Appearance: /
• Density: 2.154 g/cm³
• Vapor Pressure: 1.67E-05mmHg at 25°C
• Refractive Index: 1.744
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 6-BROMO-4-IODOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-IODOQUINOLINE(927801-23-8)
• EPA Substance Registry System: 6-BROMO-4-IODOQUINOLINE(927801-23-8)

Safety Data

• Hazardous Substances Data: 927801-23-8(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-iodoquinoline is a chemical compound that consists of a quinoline ring with bromine and iodine atoms attached to it. It is primarily used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical drugs and compounds. 6-BROMO-4-IODOQUINOLINE is commonly employed in the development of potential cancer treatments, antimalarial drugs, and other therapeutic agents due to its unique properties and reactivity. Its ability to serve as a synthon for the construction of diverse heterocyclic structures makes it a valuable starting material in organic synthesis. Additionally, 6-Bromo-4-iodoquinoline is also utilized in the research and study of chemical reactions and mechanisms, further contributing to its significance in the field of chemistry.

InChI:InChI=1/C9H5BrIN/c10-6-1-2-9-7(5-6)8(11)3-4-12-9/h1-5H

Upstream product

• 65340-70-7 6-bromo-4-chloroquinoline 
• 106-40-1 4-bromo-aniline 
• 145369-94-4 6-bromoquinolin-4-ol 
• 187278-01-9 5-(((4-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 145369-94-4 6-bromo-3-quinolinecarboxylic acid-4-ol 
• 1086062-75-0 6-bromo-4-chloroquinoline hydrochloride 

Downstream Products

• 1208116-16-8 C₂₀H₁₄N₂ 
• 1086056-63-4 C₂₅H₁₇F₂N₅O₂S 
• 1086057-39-7 C₂₅H₁₆F₂N₄O₂S 
• 1086061-45-1 C₂₅H₁₆F₂N₄O₂S 
• 1086062-66-9 GS⁽²⁶⁴⁾K₂₁₅₈ 
• 1360537-71-8 4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-2-nitrobenzenesulfonamide 
• 1360537-72-9 2-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-4-nitrobenzenesulfonamide 
• 1360537-73-0 2,4-difluoro-N-(2-hydroxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-75-2 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-76-3 2-fluoro-4-[⁽¹⁸⁾F]fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1086063-18-4 6-bromo-4-(pyridazin-4-yl)quinoline 
• 1551455-21-0 N-(2-methoxy-5-(4-((trimethylsilyl)ethynyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1551455-28-7 2-fluoro-N-(2-methoxy-5-(4-((trimethylsilyl)ethynyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1551453-19-0 2,4-difluoro-N-(5-(4-(3-hydroxyprop-1-yn-1-yl)quinolin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 

Relevant articles and documents

PI3K/mTOR protein degradation targeting chimeric compound as well as preparation method and medical application of PI3K/mTOR protein degradation targeting chimeric compound

The invention relates to a PI3K/mTOR protein degradation targeting chimeric body (PROTAC) compound as well as a preparation method and medical application thereof. Specifically, the present inventionrelates to a compound represented by a general formula (

Identification of 3-amidoquinoline derivatives as PI3K/mTOR dual inhibitors with potential for cancer therapy

A new series of 3-amidoquinoline derivatives were designed, synthesized and evaluated as PI3K/mTOR dual inhibitors. Among them, five compounds showed potent PI3Kα inhibitory activities (IC50 50 1 μM). The representative compound 15a can significantly inhibit other class I PI3Ks, mTOR and phosphorylation of pAkt(Ser473) at low nanomolar level, suggesting that 15a was a potent PI3K/mTOR dual inhibitor. Moreover, 15a displayed favorable pharmacokinetic properties in vivo.

Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor

The phosphoinositide 3-kinase (PI3K) family is one of the most frequently activated enzymes in a wide range of human cancers; thus, inhibition of PI3K represents a promising strategy for cancer therapy. Herein, a series of benzylamine substituted arylsulfonamides were designed and synthesized as dual PI3K/mTOR inhibitors using a strategy integrating focused library design and virtual screening, resulting in the discovery of 13b (NSC765844). The compound 13b exhibits highly potent enzyme inhibition with IC50s of 1.3, 1.8, 1.5, 3.8 and 3.8?nM for PI3Kα, β, γ, δ, and mTOR, respectively. 13b was further evaluated in NCI by an in?vitro cytotoxic screening program. Broad-spectrum antitumor activities with mean GI50value of 18.6?nM against approximately 60 human tumor cell lines were found. 13b displayed favorable physicochemical properties and superior pharmacokinetic profiles for animal studies. It significantly inhibited tumor growth when administered orally in an A549 non-small-cell lung carcinoma xenograft and BEL7404 human hepatocellular carcinoma xenograft models. On the basis of its excellent in?vivo efficacy and superior pharmacokinetic profiles, 13b has been selected for further preclinical investigation as a promising anticancer drug candidate.